Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)

“…However, our results are compatible with all previous reports. Thus, in the study by Dongiovanni et al, 27 involving 55 patients receiving 2 courses of cisplatin plus vinorelbine followed by 2 courses of paclitaxel plus gemcitabine, the objective response rate was 27% after the first 2 courses but 42% after 4 courses. Another study 12 showed that alternative drug administration (docetaxel or vinorelbine) in associated with cisplatin did not improve the objective response rate.…”

“…Some studies are very similar to ours, but most involved relatively small and heterogeneous populations, ruling out meaningful comparisons. Some studies involved an early switch in chemotherapy for all the patients, regardless of the response after the first two courses, [25][26][27] while others involved only patients whose disease was controlled after the first two courses. 13,28 In addition, it is not always easy to compare response rates between the different treatments, because some authors only calculated the overall response rate for the two phases.…”

A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer

“…Interesting results were also reported after the administration of a schedule of paclitaxel/cisplatin followed by vinorelbine, followed by gemcitabine; the reported objective response rate was 55%, the overall survival 14.4 months and the 1-year survival 53% [32]. The sequential administration of vinorelbine/cisplatin, followed by paclitaxel/gemcitabine resulted in a response rate of 42% and a median survival of 10.3 months [33]. Recently, 204 patients were randomized to receive either carboplatin/gemcitabine followed by paclitaxel (arm A) or cisplatin/vinorelbine followed by docetaxel (arm B).…”